Skip to main content
SpringerLink
Log in

Management of gastric neuro-endocrine tumours in a large French national cohort (GTE)

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Introduction

Gastric neuro-endocrine tumours are rare. European guidelines for the management of neuro-endocrine tumours have been published in 2012. The aim of our survey was to study the management of gastric neuro-endocrine tumours registered in the national cohort. A prospective national cohort registers the Neuro-endocrine tumours in France since January 2003 (GTE network). We reviewed all the individual medical reports of gastric neuro-endocrine tumours in order to collect data on treatment.

Results

One hundred and ninety seven gastric neuro-endocrine tumours diagnosed between 1964 and 2013 in 20 centres were registered. For 181 cases data were considered complete for our survey. Eighty four tumours were type 1 (46.4%); five types 2 (2.8%); 52 types 3 (28.7%) and 40 types 4 (22.1%). Types 1 and 2 were first endoscopically managed in 93 and 60% of cases, respectively, whereas surgery was first done in 45 and 42%, respectively, of types 3 and 4. Systemic treatment, chemotherapy and/or somatostatin analogue, was first administered exclusively for types 3 and 4. Near 3% of types 1 and 40% of types 2 received at a time somatostatin analogue treatment. Five-year survival rates were 98.3, 100, 63.2 and 31.8% for types 1, 2, 3 and 4, respectively.

Conclusion

The great majority of gastric neuro-endocrine tumours registered in this national cohort are treated in accordance with the current guidelines. The survival rates we reported must be interpreted with caution, because this cohort registered preferentially selected patients eligible for treatment. The registration of all the gastric neuro-endocrine tumours, in particular type 1 considered as benign and type 4 not eligible for specific anti-cancer treatment must be encouraged.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. M. Fraenkel, M.K. Kim, A. Faggiano, G.D. Valk, Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract. Res. Clin. Gastroenterol. 26, 691–703 (2012)

    Article  CAS  PubMed  Google Scholar 

  2. C. Lepage, A.M. Bouvier, J.M. Phelip, C. Hatem, C. Vernet, J. Faivre, Incidence and management of malignant digestive endocrine tumours in a well-defined French population. Gut 53, 549–553 (2004)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. I.M. Modlin, K.D. Lye, M. Kidd, A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am. J. Gastroenterol. 99, 23–32 (2004)

    Article  PubMed  Google Scholar 

  4. C.S. Landry, G. Brock, C.R. Scoggins, K.M. McMasters, R.C. Martin 2nd, A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann. Surg. Oncol. 16, 51–60 (2009)

    Article  PubMed  Google Scholar 

  5. M.B. Niederle, M. Hackl, K. Kaserer, B. Niederle, Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European neuroendocrine tumour society classification: an analysis based on prospectively collected parameters. Endocr. Relat. Cancer 17, 909–918 (2010)

    Article  PubMed  Google Scholar 

  6. L. Vannella, A. Sbrozzi-Vanni, E. Lahner et al., Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment. Pharmacol. Ther. 33, 1361–1369 (2011)

    Article  CAS  Google Scholar 

  7. F. Gibril, M. Schumann, A. Pace et al., Multiple endocrine neoplasia type 1 and Zollinger- Ellison syndrome: a prospective study of 107 cases and comparison with 1,009 cases from the literature. Medicine 83, 43–83 (2004)

    Article  Google Scholar 

  8. K. Borch, B. Ahren, H. Ahlman et al., Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann. Surg. 242, 64–73 (2005)

    Article  PubMed Central  Google Scholar 

  9. G. Rindi, C. Azzoni, S. La Rosa et al., ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116, 532–542 (1999)

    Article  CAS  PubMed  Google Scholar 

  10. H. Scherübl, G. Cadiot, R.T. Jensen, T. Rösch, U. Stölzel, G. Klöppel, Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 42, 664–671 (2010)

    Article  PubMed  Google Scholar 

  11. S. Rappel, A. Altendorf-Hofmann, M. Stolte, Prognosis of gastric carcinoid tumours. Digestion 56, 455–462 (1995)

    Article  CAS  PubMed  Google Scholar 

  12. Y. Sato, H. Imamura, Y. Kaizaki et al., Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig. Endosc. 26, 377–384 (2014)

    Article  PubMed  Google Scholar 

  13. D. Thomas, A.V. Tsolakis, S. Grozinsky-Glasberg, M. Fraenkel, K. Alexandraki, S. Sougioultzis, D.J. Gross, G. Kaltsas, Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur. J. Endocrinol. 168, 185–193 (2013)

    Article  CAS  PubMed  Google Scholar 

  14. E. Merola, A. Sbrozzi-Vanni, F. Panzuto et al., Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 95, 207–213 (2012)

    Article  CAS  PubMed  Google Scholar 

  15. W.C. Chen, R.R. Warner, S.C. Ward et al., Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience. Dig. Dis. Sci. 60, 996–1003 (2015)

    Article  CAS  PubMed  Google Scholar 

  16. Y. Sato, S. Hashimoto, K. Mizuno, M. Takeuchi, S. Terai, Management of gastric and duodenal neuroendocrine tumors. World J. Gastroenterol. 22, 6817–6828 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  17. G. Delle Fave, D.J. Kwekkeboom, E. Van Cutsem, G. Rindi, B. Kos-Kudla, U. Knigge, H. Sasano, P. Tomassetti, R. Salazar, P. Ruszniewski, ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 95, 74–87 (2012)

    Article  CAS  PubMed  Google Scholar 

  18. E. Solcia, G. Kloppel, L.H. Sobin, Histological typing of endocrine tumours. In international histological classification of tumours, 2nd edn. (Springer, Berlin Heidelberg, 2000) pp. 61–68

    Book  Google Scholar 

  19. L.H. Sobin, M. Gospodarowicz, C. Wittekind (eds.), UICC (International Union Against Cancer). TNM classification of malignant tumours. 7th edn. (Wiley-Blackwell, New York, 2009)

    Google Scholar 

  20. C. Lepage, B. Rachet, M.P. Coleman, Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 132, 899–904 (2007)

    Article  PubMed  Google Scholar 

  21. C. Lepage, L. Ciccolallo, R. De Angelis, A.M. Bouvier, J. Faivre, G. Gatta, The EUROCARE working group, European disparities in malignant digestive endocrine tumours survival. Int. J. Cancer 126, 2928–2934 (2010)

    CAS  PubMed  Google Scholar 

  22. M.H. Kulke, L.B. Anthony, D.L. Bushnell, W.W. de Herder, S.J. Goldsmith, D.S. Klimstra, S.J. Marx, J.L. Pasieka, R.F. Pommier, J.C. Yao, R.T. Jensen, North American neuroendocrine tumor society (NANETS), NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39, 735–752 (2010)

    Article  PubMed  PubMed Central  Google Scholar 

  23. R.A. Gladdy, V.E. Strong, D. Coit, P.J. Allen, H. Gerdes, J. Shia, D.S. Klimstra, F.B. Murray, L.H. Tang, Defining surgical indications for type I gastric carcinoid tumor. Ann. Surg. Oncol. 16, 3154–3160 (2009)

    Article  PubMed  Google Scholar 

  24. D. Ravizza, G. Fiori, C. Trovato, N. Fazio, G. Bonomo, F. Luca, L. Boder, G. Pelosi, D. Tamayo, C. Crosta, Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig. Liver. Dis. 39, 537–543 (2007)

    Article  CAS  PubMed  Google Scholar 

  25. S. Manfredi, M. Pagenault, A.S. de Lajarte-Thirouard, J.F. Bretagne, Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur. J. Gastroenterol. Hepatol. 19, 1021–1025 (2007)

    Article  PubMed  Google Scholar 

  26. S. Grozinsky-Glasberg, G. Kaltsas, C. Gur, E. Gal, D. Thomas, S. Fichman, K. Alexandraki, D. Barak, B. Glaser, I. Shimon, D.J. Gross, Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur. J. Endocrinol. 159, 475–482 (2008)

    Article  CAS  PubMed  Google Scholar 

  27. D. Campana, F. Nori, R. Pezzilli, L. Piscitelli, D. Santini, E. Brocchi, R. Corinaldesi, P. Tomassetti, Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr. Relat. Cancer 15, 337–342 (2008)

    Article  CAS  PubMed  Google Scholar 

  28. M.S. Khuroo, M.S. Khuroo, N.S. Khuroo, Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. J. Gastroenterol. Hepatol. 25, 548–554 (2010)

    Article  CAS  PubMed  Google Scholar 

  29. P. Tomassetti, M. Migliori, G.C. Caletti, P. Fusaroli, R. Corinaldesi, L. Gullo, Treatment of type II gastric carcinoid tumors with somatostatin analogues. N. Engl. J. Med. 343, 551–554 (2000)

    Article  CAS  Google Scholar 

  30. D. Campana, D. Ravizza, P. Ferolla, A. Faggiano, F. Grimaldi, M. Albertelli, D. Berretti, D. Castellani, G. Cacciari, N. Fazio, A. Colao, D. Ferone, P. Tomassetti, Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine 51, 131–139 (2016)

    Article  CAS  PubMed  Google Scholar 

  31. S. Massironi, V. Sciola, M. Pia Spampatti, M. Peracchi, D. Conte, Gastric carcinoids: between underestimation and overtreatment. World J. Gastroenterol. 15, 2177–2183 (2009)

    Article  PubMed  PubMed Central  Google Scholar 

  32. A. Rinke, H.H. Müller, C. Schade-Brittinger, K.J. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U.F. Pape, M. Bläker, J. Harder, C. Arnold, T. Gress, R. Arnold, PROMID Study Group, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J. Clin. Oncol. 27, 4656–4663 (2009)

    Article  CAS  PubMed  Google Scholar 

  33. M.E. Caplin, M. Pavel, J.B. Ćwikła, A.T. Phan, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, S. Martinez, J. Blumberg, P. Ruszniewski, CLARINET Investigators, Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224–233 (2014)

    Article  PubMed  Google Scholar 

  34. D. O’Toole, G. Delle Fave, R.T. Tensen, Gastric and duodenal neuroendocrine tumours. Best Pract. Res. Clin. Gastroenterol. 26, 719–735 (2012)

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We are thankful to all the members of the two academics networks involved in this cohort: the GTE (group for the study of endocrine tumours) and RENATEN (national network for the treatment of endocrine tumours). All the patients and their family who gave consents for this study.

Funding

The study was supported by a fund from Ipsen Pharma SAS.

Author contributions

S.M.: drafted and designed the study, recruited patients, and wrote the paper. T.W., G.C.: recruited patients, revised the manuscript; E.B., R.C., P.R., T.L., A.P.L., B.G., V.R., G.R., O.Z.C., C.L.B., C.L.: recruited patients. J.M.: did the statistical analysis.

Author information

Authors and Affiliations

  1. CHU Dijon, hepato-gastroenterology unit, University of Bourgogne Franche-Comté, INSERM, LNC UMR1231, F-21000, Dijon, France

    Sylvain Manfredi & Côme Lepage

  2. Département d’Oncologie Médicale, Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437, Lyon, cedex 03, France

    Thomas Walter & Catherine Lombard-Bohas

  3. Gustave Roussy, Département d’Oncologie Endocrinienne, 94805, Villejuif cedex, France

    Eric Baudin

  4. Department of Gastroenterology and Digestive Oncology, Cochin Teaching Hospital, Paris Descartes University, Paris, France

    Romain Coriat

  5. Beaujon Hospital and Paris Diderot University, Clichy, France

    Philippe Ruszniewski

  6. CHRU de Tours, service d’Hépato-Gastroenterologie, CNRS, UMR 7292, GICC & Université Francois-Rabelais, Tours, France

    Thierry Lecomte

  7. Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France

    Anne-Pascale Laurenty

  8. Department of Internal Medicine, Endocrinology and Nutrition, Hôpitaux Universitaires de Strasbourg, Faculté de Médecine, Université de Strasbourg, Strasbourg, France

    Bernard Goichot

  9. Service d’endocrinologie et maladies métaboliques, CHU d’Angers, 4 rue Larrey, 49100, Angers, France

    Vincent Rohmer

  10. Service d’Hépato-Gastro-Entérologie, CHU Angers, Angers, France

    Guillaume Roquin

  11. CH Le Mans, Le Mans, France

    Oana-Zvetlana Cojocarasu

  12. CIC, Université de Rennes 1, Rennes, France

    Jeff Morcet

  13. Department of Hepato-Gastroenterology and Digestive Oncology, Robert-Debré University Hospital, Reims, France

    Guillaume Cadiot

Authors
  1. Sylvain Manfredi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric Baudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Romain Coriat
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philippe Ruszniewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thierry Lecomte
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anne-Pascale Laurenty
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bernard Goichot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Vincent Rohmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guillaume Roquin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Oana-Zvetlana Cojocarasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Catherine Lombard-Bohas
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Côme Lepage
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jeff Morcet
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Guillaume Cadiot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sylvain Manfredi.

Ethics declarations

Conflict of interest

authors declare that they have no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the scientific committee of the national group for NETs (GTE) and the ethic committee of the university hospital of Rennes, France.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manfredi, S., Walter, T., Baudin, E. et al. Management of gastric neuro-endocrine tumours in a large French national cohort (GTE). Endocrine 57, 504–511 (2017). https://doi.org/10.1007/s12020-017-1355-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-017-1355-9

Keywords

Search

Navigation